TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03108976

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral assessments
Description: Kinematics measures, concomitant to Magnetoencephalography (MEG, measures oscillatory rhythms in the brain) and Magnetic Resonance Imaging (MRI, used to provide an anatomical image of each participant's brain to be coregistered with oscillatory measurements) recordings, enable to track sensori-motor learning based on performance, and oscillatory changes (with high temporal and spatial resolution).

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Behavioral assessments
Description: Kinematics measures, concomitant to Magnetoencephalography (MEG, measures oscillatory rhythms in the brain) and Magnetic Resonance Imaging (MRI, used to provide an anatomical image of each participant's brain to be coregistered with oscillatory measurements) recordings, enable to track sensori-motor learning based on performance, and oscillatory changes (with high temporal and spatial resolution).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Magnetoencephalography (MEG)
Description: Kinematics measures, concomitant to Magnetoencephalography (MEG, measures oscillatory rhythms in the brain) and Magnetic Resonance Imaging (MRI, used to provide an anatomical image of each participant's brain to be coregistered with oscillatory measurements) recordings, enable to track sensori-motor learning based on performance, and oscillatory changes (with high temporal and spatial resolution).

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Magnetoencephalography (MEG)
Description: Kinematics measures, concomitant to Magnetoencephalography (MEG, measures oscillatory rhythms in the brain) and Magnetic Resonance Imaging (MRI, used to provide an anatomical image of each participant's brain to be coregistered with oscillatory measurements) recordings, enable to track sensori-motor learning based on performance, and oscillatory changes (with high temporal and spatial resolution).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging (MRI)
Description: Kinematics measures, concomitant to Magnetoencephalography (MEG, measures oscillatory rhythms in the brain) and Magnetic Resonance Imaging (MRI, used to provide an anatomical image of each participant's brain to be coregistered with oscillatory measurements) recordings, enable to track sensori-motor learning based on performance, and oscillatory changes (with high temporal and spatial resolution).

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Magnetic Resonance Imaging (MRI)
Description: Kinematics measures, concomitant to Magnetoencephalography (MEG, measures oscillatory rhythms in the brain) and Magnetic Resonance Imaging (MRI, used to provide an anatomical image of each participant's brain to be coregistered with oscillatory measurements) recordings, enable to track sensori-motor learning based on performance, and oscillatory changes (with high temporal and spatial resolution).
Study: NCT01073319

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of placebo pill

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivastigmine
Description: Participants will be randomized to rivastigmine (1.5 mg bid) for 6 days of each phase.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivastigmine
Description: Participants will be randomized to rivastigmine (3 mg bid) for 6 days of each phase.
Study: NCT03781245

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: All the Right Moves for Subcontractors
Description: All the Right Moves for Subcontractors aims to improve safety, health and wellbeing, through the development of a communication infrastructure with supplemental tools where construction workers and company mangers work together to collaboratively identify problems and strategies to improve their conditions of work. The intervention is grounded in the key characteristics of integrated organizational interventions to improve workers' health safety and wellbeing detailed in Harvard Center for Work, Health and Wellbeing's Implementation Guidelines (McLellan et al, 2016).~The intervention involves a cyclical approach through which the research team facilitate a participatory process to identify workers' health concerns, prioritize these concerns, use an action planning process to identify and operationalize solutions, and develop a company-specific evaluation plan to measure change.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: All the Right Moves for Subcontractors
Description: All the Right Moves for Subcontractors aims to improve safety, health and wellbeing, through the development of a communication infrastructure with supplemental tools where construction workers and company mangers work together to collaboratively identify problems and strategies to improve their conditions of work. The intervention is grounded in the key characteristics of integrated organizational interventions to improve workers' health safety and wellbeing detailed in Harvard Center for Work, Health and Wellbeing's Implementation Guidelines (McLellan et al, 2016).~The intervention involves a cyclical approach through which the research team facilitate a participatory process to identify workers' health concerns, prioritize these concerns, use an action planning process to identify and operationalize solutions, and develop a company-specific evaluation plan to measure change.
Study: NCT01682798

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo yoghurt
Description: 100g of placebo yoghurt will be taken at 10:00 am and 4:00 pm, respectively; 2 times per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Yili Chang Qing Pro-ABB yoghurt (Formula 1)
Description: 100g of Yili Chang Qing Pro-ABB yoghurt will be taken by at 10:00 am and 4:00 pm, respectively; 2 times per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Yili Chang Qing Pro-ABB yoghurt (Formula 2)
Study: NCT02316262

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Targeted Muscle Reinnervation
Description: Targeted reinnervation (TR) is a surgical procedure originally designed to provide intuitive control of upper limb prostheses through transfers of residual nerves to otherwise redundant target muscle. Native motor innervation of the target muscle is cut, and the residual nerves-after excision of end-neuromas-are coapted to the motor end point of the motor nerve, close to its point of entry into the muscle. The central principle underlying the nerve transfers in TR surgery is to reestablish the function of the amputated nerve and allow intuitive, seamless prosthesis control.
Study: NCT02735434

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based ACT
Description: The guided internet program consists of 7 modules activated consecutively over a period of 12 weeks. The content is written psycho education, patient videos, audio-exercises and behavioural exposure exercises. The program is therapist-guided; hence all patients will receive support from primarily the same therapist during the 12 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Internet-based discussion forum
Description: The online discussion forum consists of 7 themes touching upon the impact of health anxiety and the patients own coping strategies. The themes are activated consecutively over a period of 12 weeks. The discussion forum is text-based, and only patients will participate in the discussion. The written discussions will be reviewed by a professional for ethical reasons. The discussion forum aims to control for the effect of attention and contacts to the health care system. After 9 months patients in the discussion forum are offered active treatment, but not as part of the research project.
Study: NCT04012086

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy
Description: Our physical therapy program included a variety of different exercise modalities (aerobic exercises, treadmill training and exercise intervention program) performed under the supervision of a physiotherapist
Study: NCT04683341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Alafenamide Tablets
Description: Approximately 100 adults, cirrhotic or non-cirrhotic (capped at 50), CHB patients with hepatic decompensation, will receive initial treatment (Arm A) with or switch (Arm B) to TAF 25 mg/day for 144 weeks. For Initiation Arm (Arm A), CHB patients with hepatic decompensation, who are currently not under HBV antiviral treatment will be enrolled. For Switch Arm (Arm B), CHB patients who are currently with hepatic decompensation and virally suppressed under HBV NUC treatment (HBV DNA \< 20 IU/mL) will be enrolled.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Alafenamide Tablets
Description: Approximately 100 adults, cirrhotic or non-cirrhotic (capped at 50), CHB patients with hepatic decompensation, will receive initial treatment (Arm A) with or switch (Arm B) to TAF 25 mg/day for 144 weeks. For Initiation Arm (Arm A), CHB patients with hepatic decompensation, who are currently not under HBV antiviral treatment will be enrolled. For Switch Arm (Arm B), CHB patients who are currently with hepatic decompensation and virally suppressed under HBV NUC treatment (HBV DNA \< 20 IU/mL) will be enrolled.
Study: NCT01177995

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Network Intervention
Description: Social network leaders will communicate HIV prevention messages to members of their social networks.
Study: NCT05809102

Intervention type: PROCEDURE
Group type: OTHER
Intervention: repair of flexor tendon in Zone II
Description: Repair of Zone II flexor tendon of the hand using minimal incisions instead of whole tendon exposure
Study: NCT00479219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSI-953

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02573545

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Planning@IFE and Standard@IFE Software

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MR Syngo (Numaris/4) software
Study: NCT00741208

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Soy Isoflavone
Description: 50mg soy isoflavone supplement consumed twice daily for a total of 100mg of soy isoflavones per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Soy Isoflavone
Description: 50mg soy isoflavone supplement consumed twice daily for a total of 100mg of soy isoflavones per day.
Study: NCT04482192

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic paravertebral block
Description: After ending pulmonary procedure, a pleural pouch created beside vertebral column, a catheter is inserted to the pouch for continuous infusion of 1% lidocaine for 3 postoperative days. Intravenous morphine sulfate (0.05mg/kg) was given as a rescue medication if the VAS ≥ 4.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systemic analgesia
Description: Systemic analgesia (SA) group receive 1gm paracetamol and 30 mg ketorolac by intravenous infusion every 6 hours for 3 days. Intravenous morphine sulfate (0.05mg/kg) was given as a rescue medication if the VAS ≥ 4.
Study: NCT00532246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: raloxifene

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00752245

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dialysis during 4 hours
Description: Blood and dialysate sampling

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dialysis during 6 hours
Description: Blood and dialysate sampling

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dialysis during 8 hours
Description: Blood and dialysate sampling
Study: NCT03592004

Intervention type: OTHER
Intervention: neoadjuvant chemotherapy
Description: neoadjuvant chemotherapy

Intervention type: OTHER
Intervention: neoadjuvant chemotherapy
Description: neoadjuvant chemotherapy

Intervention type: OTHER
Intervention: neoadjuvant chemotherapy
Description: neoadjuvant chemotherapy

Intervention type: OTHER
Intervention: neoadjuvant chemotherapy
Description: neoadjuvant chemotherapy

Intervention type: OTHER
Intervention: neoadjuvant chemotherapy
Description: neoadjuvant chemotherapy

Intervention type: OTHER
Intervention: neoadjuvant chemotherapy
Description: neoadjuvant chemotherapy

Intervention type: OTHER
Intervention: neoadjuvant chemotherapy
Description: neoadjuvant chemotherapy
Study: NCT00869271

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tac + folfox4
Description: tac: oxaliplatin 100mg + fudr 1g + mmc 10mg~folfox4~Folfox4 chemotherapy was done within 28 days after primary surgery. Per 3 weeks, patients will receive one cycle. After 3 cycles, patients will received transhepatic arterial chemotherapy(TAC) using oxaliplatin, fudr and mmc. Then begin folfox4 again.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Folfox4
Description: folfox4~Folfox4 chemotherapy was done within 28 days after primary surgery. Per 3 weeks, patients will receive one cycle
Study: NCT05972798

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Description: 2.2 g/d omega-3 PUFAs (1.2g EPA and 1g DHA per day) in patients with LLD

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Soybean oil
Description: Soybean oil in patients with LLD
Study: NCT01162720

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Short duration tourniquet
Description: Patients assigned to this arm will have the tourniquet applied during cement fixation of the prosthesis only (ie removed just prior to wound closure).
Study: NCT04234594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1203
Description: 6 mg/kg intravenous (IV) infusion only once，on the first day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vectibix®
Description: 6 mg/kg intravenous (IV) infusion only once，on the first day.
Study: NCT03834714

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Near Infrared Light
Description: NIR Light Therapy will be administered with the Earlight Generation 1.4 device during 2 out of the 4 sessions. It will be administered to each ear individually for 30 minutes per ear.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Noise Stimulus
Description: Noise stimulus will be administered, open ear, to continuous broadband noise up to 25% of the allowable daily dose of noise per the AFI 48-127 Occupational Noise and Hearing Conservation Program.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Noise Stimulus
Description: Noise stimulus will be administered, open ear, to continuous broadband noise up to 25% of the allowable daily dose of noise per the AFI 48-127 Occupational Noise and Hearing Conservation Program.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Near Infrared Light
Description: Sham NIR Light Therapy will be administered with the Earlight Generation 1.4 device during 2 out of the 4 sessions. It will be administered to each ear individually for 30 minutes per ear.
Study: NCT01048684

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mannitol
Description: Variation of mannitol dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannitol
Description: Variation of mannitol dose
Study: NCT02304354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: For rheumatoid arthritis, MabThera is given as two intravenous infusions of 1000 mg with a two-week interval between them. Patients usually respond to treatment within 16 to 24 weeks of initial treatment. After 24 weeks, treatment can be repeated depending on the patient's response.
Study: NCT04284163

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gamification
Description: Teaching through gamification

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional teaching
Description: Teaching through master lesson methodology
Study: NCT02247232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Z-100

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04679948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Percoffedrinol®
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coumadin®
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antra MUPS®
Description: Gastro-resistant tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam-ratiopharm®
Description: Oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 730357
Description: Film-coated tablet
Study: NCT04081857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP1810
Description: HGP1810: Vildagliptin/Metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP1810
Description: HGP1810: Vildagliptin/Metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1704
Description: HCP1704: Vildagliptin/Metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1704
Description: HCP1704: Vildagliptin/Metformin
Study: NCT00623857

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zinc
Description: Daily oral supplementation with zinc, 10 mg, for an average of 60 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamins and minerals other than zinc
Description: Daily supplementation with vitamin A, vitamin B1, vitamin B2, niacin, vitamin B6, folic acid, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K, iron, iodine, copper, selenium, magnesium and calcium; for an average of 60 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamins plus zinc and other minerals
Description: Daily oral supplementation with zinc, vitamin A, vitamin B1, vitamin B2, niacin, vitamin B6, folic acid, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K, iron, iodine, copper, selenium, magnesium and calcium; for an average of 60 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily oral supplementation with placebo for vitamins and all minerals; for an average of 60 weeks
Study: NCT05018988

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral vitamin D spray
Description: 1 spray (10µg) /day for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 spray / day for 12 weeks
Study: NCT02614404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib combination therapy
Description: Imatinib plus dihydroartemisinin plus piperaquine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dihydroartemisinin-piperaquine
Description: Standard of care
Study: NCT02540967

Intervention type: DRUG
Intervention: Gadobutrol (Gadavist/Gadovist, BAY86-4875)
Description: Gadovist dosage following summary of product characteristics
Study: NCT00055497

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Double-blind (DB) adalimumab placebo
Description: Double-blind nonactive matching subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DB adalimumab 40 mg eow
Description: Double-blind adalimumab 40 mg every other week by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DB adalimumab 40 mg ew
Description: Double-blind adalimumab 40 mg every week by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OL adalimumab 40 mg
Description: Open-label adalimumab every other week or every week by subcutaneous injection
Study: NCT03613688

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Deepure
Description: Pu'erh Tea extract

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Deepure
Description: Pu'erh Tea extract

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Deepure
Description: Pu'erh Tea extract

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Deepure
Description: Pu'erh Tea extract
Study: NCT00692497

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: one stop (Electronic standardised referrals and appointment bookings)
Description: The one stop strategy is a set of interventions directed at GPs referring to the University Hospital. The interventions include: Guidelines for referral, standardised electronic referrals, booking for outpatient surgery and a patient information form.
Study: NCT02036541

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AqueSys XEN 45 Glaucoma Implant
Description: Placement of the AqueSys XEN 45 Glaucoma Implant in the study eye
Study: NCT01179646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg DR Tablet vs. Protonix 40 mg DR Tablet
Description: Single dose crossover BE study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole 40 mg DR Tablet vs. Protonix 40 mg DR Tablet
Description: Single dose crossover BE study
Study: NCT01075464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEGF0444A
Description: Intravenous escalating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEGF0444A
Description: Intravenous escalating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Intravenous repeating dose
Study: NCT02548715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02419651

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Women will receive oral tramadol 100 mg 1 hour before the procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Description: Women will receive 100 mg diclofenac 1 hour before the procedure

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Women will receive a placebo 1 hour before the procedure
Study: NCT01777139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retigabine IR
Description: Retigabine IR tablets will be available in 5 strengths: 50 mg, 100 mg, 200 mg, 300 mg, and 400 mg.
Study: NCT04165135

Intervention type: DRUG
Intervention: Standard of Care for Haemophilia A
Description: There is no pre-determined studied medicinal product. Any treatment (including treatments started during the observational period) will be administered according to standard clinical practice, independently of participation in the current study, according to clinician's independent therapeutic decision.